Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy
- 1 January 1988
- journal article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 39 (1-3) , 3-7
- https://doi.org/10.1016/0163-7258(88)90032-0
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Role of glutathione and other endogenous thiols in radiation protectionPharmacology & Therapeutics, 1988
- WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.Journal of Clinical Oncology, 1987
- Phase I/II trials of WR-2721 and cis-platinumInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Treatment of Hypercalcemia in Parathyroid Cancer with WR-2721,5-2(3aminopropylamino) Ethyl-Phosphorothioic AcidAnnals of Internal Medicine, 1985
- Phase I trials of WR-2721 and cis-platinumInternational Journal of Radiation Oncology*Biology*Physics, 1984
- Phase I Controlled trials of WR-2721 and cyclophosphamideInternational Journal of Radiation Oncology*Biology*Physics, 1984
- Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent)New England Journal of Medicine, 1983
- The use of drugs which deplete intracellular glutathione in hypoxic cell radiosensitizationInternational Journal of Radiation Oncology*Biology*Physics, 1982
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 1979
- Radiobiological and Biochemical Studies of Thiophosphate Radioprotective Compounds Related to CysteamineRadiation Research, 1971